Fiche société
Gracell Biotechnologies (Shanghai) Co., Ltd.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| GC012F InjectionThis is a single-arm, open-label, multicenter, phase 1/2 clinical study to assess the safety and efficacy of GC012F Injection in subjects with refractory Systemic Lupus Erythematosus (SLE). | Lupus | Phase 1/2 | À vérifier | China | À vérifier |
| GC012F InjectionThis is a single-arm, open-label, multicenter, phase 1/2 clinical study to assess the safety and efficacy of GC012F Injection in subjects with refractory Systemic Lupus Erythematosus (SLE). | Lupus | Phase 1/2 | À vérifier | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| GC012F Injection | Lupus | Phase 1/2 | NCT06530849 | A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||